Status:
TERMINATED
A Randomized, Controlled Trial to Evaluate CT Image Quality Lumentin® 44
Lead Sponsor:
Lument AB
Conditions:
Subjects Referred to CT-examination of the Abdomen
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Subjects referred for abdominal or thoracoabdominal CT-examination will be randomised to either the three contrast agents Lumentin® 44, Omnipaque® or Movprep. The difference in contrast density, as ob...
Eligibility Criteria
Inclusion
- Subjects of either gender at least 18 years at the time of signing the informed consent.
- Having a clinical indication for CT-examination of the abdomen
Exclusion
- IV administration of iodine is contraindicated
- Known allergy to egg albumen
- Clinical suspicion, according to medical record, of fistula formation and/or leakage
- Referral indication of small bowel disease(s)
- Having known manifest thyrotoxicosis
- Having known phenylketonuria
- Having known Glucose-6-phosphatase deficiency
Key Trial Info
Start Date :
November 28 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 15 2019
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT03326518
Start Date
November 28 2017
End Date
February 15 2019
Last Update
October 27 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of medical imaging and function
Malmo, Sweden, 20502